

PATENT



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

St. Louis, Missouri  
April 6, 2000

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited in the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on April 6, 2000.

A handwritten signature in black ink, appearing to read "Charles E. Dunlap".

Charles E. Dunlap  
Reg. No. 35,124

In re application of: Wold	:	
Serial No.: 09/111,911	:	Examiner Gai Lee
Filed: July 8, 1998	:	Group Art Unit 1632
For: Inhibiting Apoptosis With Adenovirus	:	
RID Protein	:	
	:	

Assistant Commissioner for Patents  
Washington, D.C. 20231

STATEMENT OF CONTENT 37 C.F.R. §1.821(f)

In accordance with 37 C.F.R. §1.821(f), I hereby state that the content of the paper and computer readable copies of the Sequence Listing submitted under 37 C.F.R. 1.821(c) and (e), respectively, are the same.

Respectfully submitted,

A handwritten signature in black ink, appearing to read "Charles E. Dunlap".

Charles E. Dunlap  
Reg. No. 35,124  
Howell & Haferkamp, L.C.  
7733 Forsyth Boulevard, Suite 1400  
St. Louis, Missouri 63105  
(314) 727-5188

April 6, 2000

BEST AVAILABLE COPY

APR 12 1988

Application No.: 09/111,911

App

U.S. PATENT & TRADEMARK OFFICE  
**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING  
NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

- 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
- 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked-up "Raw Sequence Listing."
- 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- 6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- 7. Other: \_\_\_\_\_

**Applicant Must Provide:**

- An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216  
For CRF Submission Help, call (703) 308-4212  
For PatentIn software help, call (703) 308-6856

**PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE**

**BEST AVAILABLE COPY**